

Completion of CMC, GLP-tox Testing, Clinical Trial Medication Production, and IND Approval for Orally Administerable CD39 Target Inhibitor Preclinical Candidate Substance

SCBIO Inc.



ONCOLOGY		Preclinical
Product Type	Small Molecule	
Indication	Solid cancer, Pancreatic Cancer	
Target	CD39	
MoA(Mechanism of Action)	Potent anti-tumor effect through boosting of anti-tumoral immunity in Tumor-associated microenvironment	
Competitiveness	Down stream target of ATP/ADO signal axis, CD73 inhibitors such as Quemlistat (clinical phase 1b) Superiority of CD39 as drug target compared to CD73	
Development Stage	Currently under CMC development, In this year (2024), it will be entered to GLP-tox for 2025 clinical trial	
Route of Administration	Oral administration	